Streetbeat News

Earnings

AMC

GME

KOSS

Koss Corp (NASDAQ:KOSS) has experienced a significant stock price surge due to Keith Gill, aka 'Roaring Kitty,' re-emerging on social media. Despite the excitement, Koss's fundamentals are weak, with declining net sales and increased net losses. Technical analysis shows a bullish trend, but caution is advised as meme stock rallies often lead to pullbacks.

Portfolio Pulse from Surbhi Jain

June 03, 2024 | 6:46 pm

BPTH

CAMP

CNSP

GME

LSCC

MBOT

SAIC

U.S. stocks traded mostly lower with the Dow Jones falling over 300 points. GameStop shares spiked 35% after a Reddit post by Roaring Kitty. Bio-Path Holdings and Microbot Medical saw significant gains due to positive news, while CalAmp Corp shares plummeted 60% following a Chapter 11 bankruptcy filing. Lattice Semiconductor and CNS Pharmaceuticals also experienced notable declines.

Portfolio Pulse from Avi Kapoor

June 03, 2024 | 6:35 pm

WMT

Over the past three months, 27 analysts have evaluated Walmart (NYSE:WMT), with the majority being somewhat bullish. Recent analyst actions have predominantly involved raising price targets and ratings, reflecting positive sentiment. Despite a slight decline in the average price target, Walmart's financial performance remains strong with high net margins, ROE, and ROA, although it faced a revenue decline of -6.85% over the last three months.

Portfolio Pulse from Benzinga Insights

June 03, 2024 | 6:00 pm

BPTH

MBOT

SAIC

Shares of Science Applications International Corporation (NASDAQ:SAIC) fell 11% following a 9% year-over-year revenue decline in Q1 2025, despite slightly beating revenue estimates and meeting EPS expectations. Other notable stock movements include Microbot Medical Inc. (NASDAQ:MBOT) jumping 92.5% after FDA approval for a clinical trial, and Bio-Path Holdings, Inc. (NASDAQ:BPTH) rising 75% following positive interim results from a Phase 2 study.

Portfolio Pulse from Avi Kapoor

June 03, 2024 | 5:56 pm

ARWR

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) announced positive topline results from its Phase 3 PALISADE study of plozasiran for treating familial chylomicronemia syndrome (FCS). The study met its primary and secondary endpoints, showing significant reductions in triglycerides and a favorable safety profile. ARWR shares rose by 7.58% following the news.

Portfolio Pulse from Vandana Singh

June 03, 2024 | 5:55 pm

AMC

BRK

CMG

COHR

DIA

EWW

GME

LSCC

PARA

QQQ

SAIC

SPOT

SPY

TLT

XLV

XRT

The VIX surged 9% as major U.S. equity indices fell due to concerns over U.S. manufacturing activity. Safe-haven assets like bonds and gold rose, while meme stocks like GameStop and AMC spiked. Notable stock movements included Paramount Global, Lattice Semiconductor, and Spotify. Mexican assets also saw significant declines following a presidential election.

Portfolio Pulse from Piero Cingari

June 03, 2024 | 5:32 pm

NIO

XPEV

Chinese EV stocks Nio, XPeng, and Li Auto saw significant attention on Monday due to strong May delivery numbers. Despite robust sales growth, shares of all three companies traded lower, likely due to concerns over price wars and weakening demand.

Portfolio Pulse from Anusuya Lahiri

June 03, 2024 | 5:09 pm

PGEN

Precigen (NASDAQ:PGEN) has been analyzed by 6 analysts, showing a range of bullish to somewhat bullish sentiments. The average 12-month price target has increased by 29.07% to $8.17. Despite positive analyst ratings, Precigen faces financial challenges with declining revenue, negative net margin, and low ROE and ROA.

Portfolio Pulse from Benzinga Insights

June 03, 2024 | 5:00 pm

AFMD

Affimed N.V. (NASDAQ:AFMD) shares surged after the company announced promising follow-up data from its AFM24-102 study in non-small cell lung cancer (NSCLC). The study showed significant efficacy in heavily pretreated patients, leading to a positive market reaction and a reiterated Buy rating from HC Wainwright & Co. with a $10 price target.

Portfolio Pulse from Erica Kollmann

June 03, 2024 | 4:58 pm

BMY

Bristol Myers Squibb (NYSE:BMY) announced positive results from multiple studies, including the Phase 3 KRYSTAL-12 study for Krazati in NSCLC and updated analyses from CheckMate studies for Opdivo and Breyanzi. These results have led to a 1.75% increase in BMY stock price.

Portfolio Pulse from Vandana Singh

June 03, 2024 | 4:51 pm